Interpace Biosciences Announces New Clinical Validation Data; Diagnostic Accuracy Significantly Improved
01 sept. 2022 17h18 HE
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant...
Interpace Biosciences Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly Improved
15 août 2022 16h05 HE
|
Interpace Biosciences, Inc.
●Q2 Revenue of $9.4 million down 16% versus Prior Year driven by an unexpected retroactive price decrease on ThyGeNEXT® ●2022 Year to Date Net Loss Improves by $1.5 million ●Days Sales Outstanding...